The Antibiotic Trimethoprim Displays Strong Mutagenic Synergy with 2-Aminopurine

Area of Science:

• Microbiology
• Genetics
• Pharmacology

Background:

• Combination therapies are common in antibiotic and cancer treatments.
• The mutagenic potential of drug combinations is often overlooked.
• Antibiotics like trimethoprim (TMP) are widely used.

Purpose of the Study:

• To investigate the synergistic mutagenic effects of trimethoprim (TMP) and 2-aminopurine (2AP) in Escherichia coli.
• To analyze the impact of combined drug treatments on mutation frequencies and spectra.
• To understand the underlying molecular mechanisms, specifically alterations in deoxynucleoside triphosphate (dNTP) ratios.

Main Methods:

• Utilized the rpoB-Rif(r) system in Escherichia coli to quantify mutation frequencies.
• Administered trimethoprim (TMP) alone, 2-aminopurine (2AP) alone, and in combination.
• Analyzed mutational spectra to identify patterns induced by individual agents and their combination.
• Investigated the effect of the frameshift mutagen ICR191 in combination with 2AP.

Main Results:

• The combination of TMP and 2AP resulted in a 35-fold increase in mutation frequencies.
• The synergistic mutagenic effect was linked to an alteration in dNTP ratios, not observed with individual agents.
• A similar, though less pronounced, mutagenic response was observed with ICR191 and 2AP.

Conclusions:

• Trimethoprim (TMP) exhibits significant synergistic mutagenicity when combined with 2-aminopurine (2AP).
• Combined antibiotic therapies can induce mutagenic effects via altered dNTP pools.
• There is a critical need to evaluate the mutagenic potential of drug combinations in clinical settings.